Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kuaiwei Tablet is a Traditional Chinese Medicine (TCM) formulation primarily indicated for the treatment of chronic superficial gastritis, gastric ulcers, and associated epigastric pain. The formulation typically consists of *Rhizoma Corydalis* (Yanhusuo), *Alumen* (Kufan), and *Os Sepiae* (Haipiaoxiao). It works through a multi-targeted approach: neutralizing excess gastric acid via its mineral components and providing analgesic relief through the alkaloids found in *Rhizoma Corydalis*. Clinical research, including studies conducted by Xiyuan Hospital of the China Academy of Chinese Medical Sciences, has focused on its efficacy in reducing upper abdominal pain and its potential role in managing *Helicobacter pylori* infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kuaiwei Tablet.